Related search

Long-Term Outcome of Anemic Lower-Risk Myelodysplastic Syndromes Without 5q Deletion Refractory to or Relapsing After Erythropoiesis-Stimulating Agents

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica
Hematology
2008English

PUK32 Lower Case Mix Adjusters Are Associated With Lower Erythropoiesis-Stimulating Agent (ESA) and Other Bundled Costs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

Familial Clubfoot With or Without Associated Lower Limb Anomalies

2020English

Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

Annals of Hematology
MedicineHematology
2009English

The Role of Ineffective Erythropoiesis in Non-Transfusion-Dependent Thalassemia

Blood Reviews
OncologyHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy